First Quarter 2026 Revenue Increased 13% Year-over-YearWARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026 and Business Highlights Helped a record of over 45,000 children in the first quarter of 2026Generated total revenue of $59.4 million for the first quarte ...

HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region, will host a conference call on Thursday, May 14, 2026, at 5:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2026. The Company’s results will be reported in a press release prior to the call. PEDEVCO’s management will host ...

Safehold Reports First Quarter 2026 Results Accessibility Statement Skip NavigationNEW YORK, April 30, 2026 /PRNewswire/ -- Safehold Inc. (NYSE: SAFE) reported results for the first quarter 2026.SAFE published a presentation detailing these results which can be found on its website, www.safeholdinc.com in the "Investors" section.Highlights from the earnings announcement include:Q1'26 revenue was $110.9 millionQ1'26 net income attributable to common shareholders was $28.9 millionQ1'26 earnings per share was ...

文章核心观点 - Larimar Therapeutics公司宣布其核心候选药物nomlabofusp（用于治疗弗里德赖希共济失调）的临床前和临床数据在同行评审期刊上发表 这些数据支持了皮肤中Frataxin（FXN）蛋白水平可作为合理的替代终点 并计划通过加速批准途径推进其注册项目及在2026年6月提交生物制品许可申请[1][2][3] 药物研发进展与数据 - 临床前数据显示 在小鼠、大鼠和非人灵长类动物中 nomlabofusp治疗能持续增加与弗里德赖希共济失调相关的临床组织中的Frataxin（FXN）水平[2] - 在动物模型中观察到的FXN水平增加 与在皮肤和口腔颊细胞等易获取的外周组织中观察到的水平具有相关性[2] - 在弗里德赖希共济失调患者中 给药nomlabofusp后 同样观察到皮肤和口腔颊细胞这两种外周组织中FXN水平增加的相关性[2] - 这些数据已作为支持材料包的一部分提交给美国FDA 以支持将皮肤FXN浓度作为公司注册项目中“合理可能的替代终点”的潜在用途[2] 公司战略与监管路径 - 公司计划为其nomlabofusp项目寻求加速批准途径[2] - 基于已获得的数据 公司计划在2026年6月提交生物制品许可申请[3] - 公司正专注于持续推进其近期的注册里程碑 并致力于将nomlabofusp打造为针对弗里德赖希共济失调患者的首个潜在疾病修饰疗法[3] 公司背景与平台 - Larimar Therapeutics是一家专注于开发治疗复杂罕见病的临床阶段生物技术公司[4] - 其先导化合物nomlabofusp正在被开发为弗里德赖希共济失调的潜在疗法[4] - 公司还计划利用其细胞内递送平台 设计其他融合蛋白 以靶向治疗其他以细胞内生物活性化合物缺乏为特征的罕见疾病[4]

FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will publish its first quarter 2026 financial results before market open on Friday, May 8, 2026. Alamar Biosciences plans to host and webcast its first earnings conference call as a public company in August 2026 to report second quarter 2026 financial results. About Alamar Biosciences, Inc. Alamar is a life s ...

MINNEAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (NASDAQ: JCAP) (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off, insolvency and active consumer accounts, today announced that it will release financial results for the first quarter 2026 after the market close on Thursday, May 14, followed by a webcast at 5:00 pm Eastern Time that day to discuss the Company’s results. The live webcast and archived replay can be accessed in the investor relations ...

MENLO PARK, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.31 per share of common stock to be paid on June 18, 2026 to all common stockholders of record as of June 5, 2026. Exponent has paid, and expects to continue to pay, quarterly dividends each year in March, June, September, and December. Future declarations of quarterly dividends and the establishment of future record and payment dates ar ...

CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026PHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the company will deliver an oral presentation at the American Diabet ...

公司融资与工厂建设 - 公司将从美国能源部获得高达45亿美元的贷款用于佐治亚州工厂建设 [1] - 此次获批的贷款额度较先前批准的额度减少了约20亿美元 [1] 公司资金使用 - 公司将提取该笔贷款资金用于工厂建设 [1]

SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at three upcoming investor conferences in May and June. 2026 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Tuesday, May 12 at 3:40pm PT / 6:40pm ET 46th Annual William Blair Growth Stock Conference Locati ...